194 related articles for article (PubMed ID: 37865722)
1. Liquid biopsy epigenomic profiling for cancer subtyping.
Baca SC; Seo JH; Davidsohn MP; Fortunato B; Semaan K; Sotudian S; Lakshminarayanan G; Diossy M; Qiu X; El Zarif T; Savignano H; Canniff J; Madueke I; Saliby RM; Zhang Z; Li R; Jiang Y; Taing L; Awad M; Chau CH; DeCaprio JA; Figg WD; Greten TF; Hata AN; Hodi FS; Hughes ME; Ligon KL; Lin N; Ng K; Oser MG; Meador C; Parsons HA; Pomerantz MM; Rajan A; Ritz J; Thakuria M; Tolaney SM; Wen PY; Long H; Berchuck JE; Szallasi Z; Choueiri TK; Freedman ML
Nat Med; 2023 Nov; 29(11):2737-2741. PubMed ID: 37865722
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer.
Roy D; Tiirikainen M
Trends Cancer; 2020 Feb; 6(2):78-81. PubMed ID: 32061307
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
4. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
5. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
6. Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA.
Sunami K; Bando H; Yatabe Y; Naito Y; Takahashi H; Tsuchihara K; Toyooka S; Mimori K; Kohsaka S; Uetake H; Kinoshita I; Komine K; Takeda M; Hayashida T; Tamura K; Nishio K; Yamamoto N;
Cancer Sci; 2021 Sep; 112(9):3911-3917. PubMed ID: 34128569
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
Giannopoulou L; Kasimir-Bauer S; Lianidou ES
Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
[TBL] [Abstract][Full Text] [Related]
8. Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA.
van der Pol Y; Mouliere F
Cancer Cell; 2019 Oct; 36(4):350-368. PubMed ID: 31614115
[TBL] [Abstract][Full Text] [Related]
9. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
10. Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD; Wells JD; Shee K; Bean JR; Marotti JD; Wells WA; Trask HW; Kolling FW; Bhatt A; Kaufman PA; Schwartz GN; Gemery JM; McNulty NJ; Tsapakos MJ; Barth RJ; Arrick BA; Gui J; Miller TW
Breast Cancer Res Treat; 2020 Aug; 182(3):665-677. PubMed ID: 32562118
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D
Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR
Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
Iwahashi N; Sakai K; Noguchi T; Yahata T; Matsukawa H; Toujima S; Nishio K; Ino K
Sci Rep; 2019 Jul; 9(1):10426. PubMed ID: 31320709
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
16. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.
Gouda MA; Duose DY; Lapin M; Zalles S; Huang HJ; Xi Y; Zheng X; Aldesoky AI; Alhanafy AM; Shehata MA; Wang J; Kopetz S; Meric-Bernstam F; Wistuba II; Luthra R; Janku F
Oncologist; 2023 Apr; 28(4):368-372. PubMed ID: 36200910
[TBL] [Abstract][Full Text] [Related]
17. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
Krebs MG; Malapelle U; André F; Paz-Ares L; Schuler M; Thomas DM; Vainer G; Yoshino T; Rolfo C
JAMA Oncol; 2022 Dec; 8(12):1830-1839. PubMed ID: 36264554
[TBL] [Abstract][Full Text] [Related]
18. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
20. Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook.
Lianidou E
Mol Oncol; 2021 Jun; 15(6):1683-1700. PubMed ID: 33942482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
